RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Gilead Sciences priced its Sovaldi treatment for hepatitis C at $8,938 in China — about one-fifth the current price in the US. In 2013, when the drug originally went on sale in the US, it cost $84,000 for a three-month round of treatment. Because it was 95% effective in a difficult-to-cure population, Gilead made the case that Sovaldi was worth the high cost. In most less-developed countries — including India — Gilead allows sales of Sovaldi at less than $400 for a three-month regimen. China is not included in that group.
Source: China Biotoday
